Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits
- PMID: 32358864
- PMCID: PMC7261974
- DOI: 10.1111/dth.13490
Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits
Conflict of interest statement
The authors declare no potential conflict of interest.
Comment on
-
Biologic therapy for psoriasis during the covid-19 outbreak is not a choice.J Dermatolog Treat. 2020 Jun;31(4):320-321. doi: 10.1080/09546634.2020.1749545. Epub 2020 Apr 6. J Dermatolog Treat. 2020. PMID: 32248724 No abstract available.
References
-
- American Academy of Dermatology (AAD) . Guidance on the Use of Biologic Agents During COVID‐19 Outbreak. Rosemont, Illinois: American Academy of Dermatology; 2020. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/07b61465....
-
- International League of Dermatological Societies . Guidance on the Use of Systemic Therapy for Patients with Psoriasis/Atopic Dermatitis During the COVID‐19 (SARS‐Cov‐2, Coronavirus) Pandemic. International League of Dermatological Societies; 2020. https://ilds.org/covid-19/guidance-psoriasis-atopic-dermatitis/.
-
- International Psoriasis Council. Statement on the Coronavirus (COVID‐19) Outbreak . https://www.psoriasiscouncil.org/blog/Statement-on-COVID-19-and-Psoriasi....
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
